PMID- 27512877
OWN - NLM
STAT- MEDLINE
DCOM- 20170206
LR  - 20221207
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 95
IP  - 32
DP  - 2016 Aug
TI  - Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic 
      parameters in patients with type 2 diabetes undergoing dialysis.
PG  - e4543
LID - 10.1097/MD.0000000000004543 [doi]
LID - e4543
AB  - Hyperglycemia is associated with increased mortality and morbidity in patients 
      with type 2 diabetes mellitus (T2DM) who are undergoing dialysis. Although 
      dipeptidyl peptidase-4 (DPP-4) inhibitors have been widely used in end-stage 
      renal disease (ESRD) patients with T2DM, there are few studies on their efficacy 
      in this population. We studied the effect of 3 different DPP-4 inhibitors on 
      metabolic parameters in ESRD patients with T2DM.Two hundred ESRD patients with 
      T2DM who were treated with DPP-4 inhibitors (sitagliptin, vildagliptin, or 
      linagliptin) were enrolled and analyzed retrospectively. The changes in glycated 
      hemoglobin (HbA1c), fasting plasma glucose, and lipid profiles were assessed 
      before and after 3 months of treatment with DPP-4 inhibitors. Subgroup analysis 
      was done for each hemodialysis (HD) and peritoneal dialysis (PD) group.There was 
      no significant difference in the decrease in the HbA1c level among sitagliptin, 
      vildagliptin, and linagliptin treatment groups (-0.74 +/- 1.57, -0.39 +/- 1.45, and 
      -0.08 +/- 1.40, respectively, P = 0.076). The changes in fasting blood glucose and 
      lipid profiles were also not significantly different. In HD patients (n = 115), 
      there was no difference in the HbA1c level among the 3 groups. In contrast, in PD 
      patients (n = 85), HbA1c was reduced more after 3 months of treatment with 
      sitagliptin compared with vildagliptin and linagliptin (-1.58 +/- 0.95, 
      -0.46 +/- 0.98, -0.04 +/- 1.22, respectively, P = 0.001).There was no significant 
      difference in the glucose-lowering effect between the different DPP-4 inhibitors 
      tested in ESRD patients. In PD patients, sitagliptin tends to lower the HbA1c 
      level more than the other inhibitors. The glucose-lowering efficacy of the 3 
      DPP-4 inhibitors was comparable.
FAU - Park, Se Hee
AU  - Park SH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine 
      Department of Medicine, The Graduate School, Yonsei University College of 
      Medicine, Seoul Division of Endocrinology and Metabolism, Department of Internal 
      Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Gyeonggi 
      Division of Nephrology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul Division of Endocrinology and Metabolism, Department 
      of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.
FAU - Nam, Joo Young
AU  - Nam JY
FAU - Han, Eugene
AU  - Han E
FAU - Lee, Yong-Ho
AU  - Lee YH
FAU - Lee, Byung-Wan
AU  - Lee BW
FAU - Kim, Beom Seok
AU  - Kim BS
FAU - Cha, Bong-Soo
AU  - Cha BS
FAU - Kim, Chul Sik
AU  - Kim CS
FAU - Kang, Eun Seok
AU  - Kang ES
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Lipids)
RN  - 0 (Nitriles)
RN  - 0 (Pyrrolidines)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 3X29ZEJ4R2 (Linagliptin)
RN  - I6B4B2U96P (Vildagliptin)
RN  - PJY633525U (Adamantane)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Adamantane/analogs & derivatives/therapeutic use
MH  - Blood Glucose/analysis
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/metabolism
MH  - Diabetic Nephropathies/therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Kidney Failure, Chronic/etiology/therapy
MH  - Linagliptin/therapeutic use
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - Nitriles/therapeutic use
MH  - Peritoneal Dialysis
MH  - Pyrrolidines/therapeutic use
MH  - Renal Dialysis
MH  - Retrospective Studies
MH  - Sitagliptin Phosphate/therapeutic use
MH  - Treatment Outcome
MH  - Vildagliptin
PMC - PMC4985332
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2016/08/12 06:00
MHDA- 2017/02/07 06:00
PMCR- 2016/08/12
CRDT- 2016/08/12 06:00
PHST- 2016/08/12 06:00 [entrez]
PHST- 2016/08/12 06:00 [pubmed]
PHST- 2017/02/07 06:00 [medline]
PHST- 2016/08/12 00:00 [pmc-release]
AID - 00005792-201608090-00043 [pii]
AID - 10.1097/MD.0000000000004543 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2016 Aug;95(32):e4543. doi: 10.1097/MD.0000000000004543.